MedTrace Logo

Evaluation of IBI302 Injection in nAMD or DME

NCT05961007 · Status: SUSPENDED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2023-07-27

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of intravitreal IBI302 in the treatment of subjects with neovascular age-related macular degeneration (only in Phase I) or diabetic macular edema.

Conditions

Interventions

BIOLOGICAL

Intravitreal injection of IBI302(dose 1)

IBI302(dose 1) intravitreal injection given as protocol

BIOLOGICAL

Intravitreal injection of IBI302(dose 2)

IBI302(dose 2) intravitreal injection given as protocol

BIOLOGICAL

Intravitreal injection of IBI302(dose 3)

IBI302(dose 3) intravitreal injection given as protocol

DRUG

Intravitreal injection of Aflibercept

Aflibercept intravitreal injection given as protocol

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-18
Primary Completion
2023-10-31
Completion
2024-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05961007 on ClinicalTrials.gov